The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Gonadorelin

GnRH · Gonadotropin-Releasing Hormone

C
Animal replicated
FDA-approvedGnRH AnalogHypothalamic Peptide HormoneDecapeptide
RouteInjectableFDA-approved
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
GnRH — Gonadotropin-Releasing Hormone — Decapeptide — FDA Approved — TRT Fertility Preservation — GnRH Analog, Hypothalamic Peptide Hormone, Decapeptide.
Why people use it
Used primarily for hormonal support and sexual health.
If you only read one thing

Gonadorelin is simultaneously the most physiological approach to maintaining HPTA function during TRT — it replaces the very signal the hypothalamus would normally produce — and the most pharmacologically challenging to administer correctly. The 2-4 minute plasma half-life means that any gonadorelin injection is a brief pulse that clears within minutes; the pulsatile receptor biology requires that pulses arrive with the right frequency and amplitude. Too frequent → desensitization → suppression (the prostate cancer drug mechanism). Too infrequent → insufficient stimulation. The community TRT protocol of 100-200 mcg twice daily is a pragmatic compromise between what is physiologically ideal (a pump delivering 10 mcg every 90 minutes) and what is practically implementable for someone giving themselves injections. Whether this compromise is sufficient to maintain meaningful testicular function and spermatogenesis during TRT is the question that the evidence base, which is extrapolated from congenital hypogonadotropic hypogonadism treatment rather than TRT co-administration, cannot yet fully answer.

Check interactions →
Evidence reality check
Risk posture
No major flags listed
Review route-specific cautions before use.
Categories
Hormonal & HPTALibido & Sexual Health
Properties
✓ FDA-approvedHPTA: stimulatingNot injectable
Half-life
The 2-4 minute plasma half-life means that any gonadorelin injection is a brief pulse that clears within minutes
Evidence
CAnimal replicated
The Most Important Pharmacological Principle
The same compound — gonadorelin — produces diametrically opposite endocrine effects depending on whether it is administered in a pulsatile or continuous manner. Pulsatile gonadorelin (mimicking the hypothalamic 90-120 minute pulse pattern): stimulates pituitary GnRH receptors → LH and FSH released → testosterone and sperm production maintained. Continuous gonadorelin (non-pulsatile infusion or very frequent dosing): causes GnRH receptor desensitization and downregulation → LH and FSH suppressed → testosterone and sperm production fall. This is not a theoretical concern — it is the basis for GnRH agonist drugs (leuprolide, buserelin, histrelin) being used for chemical castration in prostate cancer and endometriosis at continuous dosing. Gonadorelin itself at community TRT doses (twice daily) attempts to exploit the pulsatile pathway. Whether this succeeds depends on whether the dosing frequency is sufficient to maintain stimulatory rather than desensitizing receptor dynamics.
Why Gonadorelin Entered TRT Practice
In March 2020, the FDA enforced against compounding pharmacies producing HCG (human chorionic gonadotropin) as a bulk drug substance, effectively ending the availability of compounded HCG that most TRT clinics had been prescribing for testicular preservation. HCG acts as an LH mimetic, directly stimulating the LH receptor on testicular Leydig cells — bypassing the pituitary entirely. When compounded HCG became unavailable, TRT clinics needed an alternative. Compounded gonadorelin emerged as the primary substitute: it acts upstream at the pituitary, stimulating natural LH and FSH production. The transition happened rapidly, making gonadorelin one of the most commonly prescribed TRT adjuncts by 2022-2023 — despite having no controlled clinical trials specifically for this TRT co-administration indication.
Gonadorelin vs HCG — The Critical Comparison
HCG: acts directly on testicular LH receptors (LH mimetic); does NOT engage the pituitary; does NOT stimulate FSH; well-documented track record for testicular preservation during TRT; HCG receptor downregulation possible with long-term continuous use. Gonadorelin: acts at pituitary GnRH receptors → stimulates both LH AND FSH; requires an intact, responsive pituitary (potentially suppressed on TRT); short half-life (~2-4 min IV; ~10-20 min SubQ) necessitates frequent dosing; more physiological (engages the full HPG axis); better for spermatogenesis (FSH is essential for sperm production). Clinical consensus: HCG is generally more effective for preserving testicular function during TRT for most men; gonadorelin's advantage is FSH stimulation for spermatogenesis, and it became the primary option when compounded HCG was restricted.
FDA Status and Compounding
FDA-approved: Factrel (100 mcg/vial; gonadorelin HCl; diagnostic testing of pituitary-gonadal axis function) and Lutrepulse (pulsatile pump GnRH; primary hypothalamic amenorrhea in women). The TRT co-administration use is off-label — no FDA-approved indication for gonadorelin in male fertility preservation or TRT adjunct. Community and clinic access: compounded gonadorelin as subcutaneous injection formulation from 503A or 503B pharmacies. The compounding status of gonadorelin as of mid-2026 is more stable than HCG — gonadorelin has FDA-approved drugs (Factrel, Lutrepulse) that establish the compound's regulatory presence, supporting compounding pharmacy operations for related formulations.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Kisspeptin-10
C
Same class · Decapeptide

Named After Hershey's Kisses. Discovered as a Metastasis Suppressor Gene. Repurposed as the Master Upstream Regulator of the Entire HPG Axis. The Most Potent Known Activator of GnRH Neurons. Human Clinical Trials in Hypogonadotropic Hypogonadism, Hypothalamic Amenorrhea, IVF Triggering, and Hypoactive Sexual Desire Disorder. Limbic Brain Activation Proven by fMRI. No FDA Approval. The Most Pharmacologically Compelling Compound in PCT That No One Has Properly Studied for PCT.

Enclomiphene
C
Shared goal · hormonal

The Pure Active Isomer in Clomid. The Drug That Raised Testosterone as Well as TRT While Preserving Fertility — and Still Failed FDA Approval. The Zuclomiphene Problem: Why the Racemic Mixture Causes Side Effects Pure Enclomiphene Shouldn't. The NDA That Died in 2021. How It Differs from TRT, HCG, and Gonadorelin for Male Hypogonadism. The 2025 Meta-Analysis: +273 ng/dL Testosterone vs Placebo.

Human Chorionic Gonadotropin
B
Shared goal · hormonal

FDA-Approved for Fertility and Male Hypogonadism. The Most Important Hormone in Post-Cycle Therapy. The Active Ingredient in the Simeons 500-Calorie Diet — a Fraud With Its Own FDA Warning. WADA S2 Banned. A Tumor Marker. Three Completely Different Identities in One Glycoprotein.

Check interactions